• Something wrong with this record ?

A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy

G. Tisci, L. Rajsiglova, S. Bibbo, G. Ziccheddu, E. Ricciardi, E. Falvo, V. De Laurenzi, G. Sala, E. Capone, G. Colotti, A. Arcovito, N. Giacon, P. Makovický, L. Sushytskyi, P. Lukac, L. Vannucci, P. Giacomini, P. Ceci

. 2025 ; 309 (Pt 1) : 142843. [pub] 20250403

Language English Country Netherlands

Document type Journal Article

To address the challenge of drug accumulation and penetration at the tumor site(s), herein we describe a first-in-class nanocarrier containing 24 copies each of two bioactive peptides (BAPs) genetically fused in frame to the 24 N-termini of a human ferritin H-type construct, named THE-10. The two BAPs are specific for PD-L1 and integrin αVβ3/αVβ5 plus Neuropilin (iRGD) respectively, conferring immune checkpoint blockade and drug-internalization properties. In turn, the THE-10 backbone brings 48 BAPs contiguous for synergism, prolonged blood half-life, and release into the tumor microenvironment upon conditional cleavage of a metalloprotease-sensitive site. Predicted THE-10 multitasking activity was experimentally supported as follows. Size-exclusion chromatography and surface plasmon resonance demonstrated BAP cleavage/release and receptor binding (nanomolar KD). Live-cell/time-lapse imaging demonstrated 4-fold-increased internalization of naked therapeutic antibodies, mirrored by enhanced cytotoxicity of the corresponding Antibody-Drug Conjugate. Slight antitumor effects were observed in vivo by treating immune checkpoint-sensitive syngeneic mouse colorectal model with THE-10 alone. Drug boosting was instead considerable on colorectal and pancreatic tumor allografts when THE-10 was co-administered with both small and large chemotherapeutic agents, outperforming the original iRGD cyclic peptide. Thus, THE-10 may enhance target therapy, chemotherapy and immunotherapy altogether, e.g. it candidates as a multitasking, all-round, antineoplastic therapy booster.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc25015874
003      
CZ-PrNML
005      
20250731091316.0
007      
ta
008      
250708s2025 ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ijbiomac.2025.142843 $2 doi
035    __
$a (PubMed)40187454
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Tisci, Giada $u Department of Biochemical Sciences, Sapienza University, Rome, Italy
245    12
$a A first-in-class non-cytotoxic nanocarrier based on a recombinant human ferritin boosts targeted therapy, chemotherapy and immunotherapy / $c G. Tisci, L. Rajsiglova, S. Bibbo, G. Ziccheddu, E. Ricciardi, E. Falvo, V. De Laurenzi, G. Sala, E. Capone, G. Colotti, A. Arcovito, N. Giacon, P. Makovický, L. Sushytskyi, P. Lukac, L. Vannucci, P. Giacomini, P. Ceci
520    9_
$a To address the challenge of drug accumulation and penetration at the tumor site(s), herein we describe a first-in-class nanocarrier containing 24 copies each of two bioactive peptides (BAPs) genetically fused in frame to the 24 N-termini of a human ferritin H-type construct, named THE-10. The two BAPs are specific for PD-L1 and integrin αVβ3/αVβ5 plus Neuropilin (iRGD) respectively, conferring immune checkpoint blockade and drug-internalization properties. In turn, the THE-10 backbone brings 48 BAPs contiguous for synergism, prolonged blood half-life, and release into the tumor microenvironment upon conditional cleavage of a metalloprotease-sensitive site. Predicted THE-10 multitasking activity was experimentally supported as follows. Size-exclusion chromatography and surface plasmon resonance demonstrated BAP cleavage/release and receptor binding (nanomolar KD). Live-cell/time-lapse imaging demonstrated 4-fold-increased internalization of naked therapeutic antibodies, mirrored by enhanced cytotoxicity of the corresponding Antibody-Drug Conjugate. Slight antitumor effects were observed in vivo by treating immune checkpoint-sensitive syngeneic mouse colorectal model with THE-10 alone. Drug boosting was instead considerable on colorectal and pancreatic tumor allografts when THE-10 was co-administered with both small and large chemotherapeutic agents, outperforming the original iRGD cyclic peptide. Thus, THE-10 may enhance target therapy, chemotherapy and immunotherapy altogether, e.g. it candidates as a multitasking, all-round, antineoplastic therapy booster.
650    _2
$a lidé $7 D006801
650    _2
$a zvířata $7 D000818
650    12
$a imunoterapie $7 D007167
650    _2
$a myši $7 D051379
650    12
$a ferritiny $x chemie $x genetika $x farmakologie $7 D005293
650    12
$a nosiče léků $x chemie $7 D004337
650    _2
$a nádorové buněčné linie $7 D045744
650    12
$a nanočástice $x chemie $7 D053758
650    _2
$a protinádorové látky $x farmakologie $x chemie $7 D000970
650    _2
$a rekombinantní proteiny $x chemie $7 D011994
655    _2
$a časopisecké články $7 D016428
700    1_
$a Rajsiglova, Lenka $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Bibbo, Sandra $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy
700    1_
$a Ziccheddu, Giovanna $u Translational Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53, Rome, Italy
700    1_
$a Ricciardi, Elena $u Translational Oncology Unit, IRCCS National Cancer Institute Regina Elena, Via Elio Chianesi 53, Rome, Italy
700    1_
$a Falvo, Elisabetta $u Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy
700    1_
$a De Laurenzi, Vincenzo $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy
700    1_
$a Sala, Gianluca $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy. Electronic address: g.sala@unich.it
700    1_
$a Capone, Emily $u Department of Innovative Technologies in Medicine & Dentistry, University of Chieti-Pescara, Chieti, Italy; Center for Advanced Studies and Technology (CAST), Italy
700    1_
$a Colotti, Gianni $u Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy
700    1_
$a Arcovito, Alessandro $u Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, Italy; Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo Agostino Gemelli 8, 00168 Rome, Italy
700    1_
$a Giacon, Noah $u Dipartimento di Scienze Biotecnologiche di Base, Cliniche Intensivologiche e Perioperatorie, Università Cattolica del Sacro Cuore, Largo F. Vito 1, Rome, Italy
700    1_
$a Makovický, Peter $u Institute of Histology and Embryology, Faculty of Medicine, University of Ostrava, Syllabova 19, Ostrava-Vítkovice, Czech Republic
700    1_
$a Sushytskyi, Leonid $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; Department of Carbohydrates and Cereals, Faculty of Food and Biochemical Technology, University of Chemistry and Technology in Prague, Technická 5, 166 28 Prague, Czech Republic
700    1_
$a Lukac, Pavol $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic; Department of Cell Biology, Faculty of Science, Charles University, Prague, Czech Republic
700    1_
$a Vannucci, Luca $u Laboratory of Immunotherapy, Institute of Microbiology, Czech Academy of Sciences, Prague, Czech Republic
700    1_
$a Giacomini, Patrizio $u UOSD Medicina di Precisione in Senologia, Fondazione Policlinico Universitario "A. Gemelli", IRCCS, Largo Agostino Gemelli 8, Rome, Italy
700    1_
$a Ceci, Pierpaolo $u Institute of Molecular Biology and Pathology, Italian National Research Council IBPM-CNR, Rome, Italy; Thena Biotech, Latina, Italy. Electronic address: pierpaolo.ceci@cnr.it
773    0_
$w MED00002295 $t International journal of biological macromolecules $x 1879-0003 $g Roč. 309, č. Pt 1 (2025), s. 142843
856    41
$u https://pubmed.ncbi.nlm.nih.gov/40187454 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20250708 $b ABA008
991    __
$a 20250731091311 $b ABA008
999    __
$a ok $b bmc $g 2366600 $s 1252999
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2025 $b 309 $c Pt 1 $d 142843 $e 20250403 $i 1879-0003 $m International journal of biological macromolecules $n Int J Biol Macromol $x MED00002295
LZP    __
$a Pubmed-20250708

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...